Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H3S5
UPID:
PIGM_HUMAN
Alternative names:
GPI mannosyltransferase I; Phosphatidylinositol-glycan biosynthesis class M protein
Alternative UPACC:
Q9H3S5
Background:
GPI mannosyltransferase 1, also known as GPI mannosyltransferase I and Phosphatidylinositol-glycan biosynthesis class M protein, plays a crucial role in glycosylphosphatidylinositol-anchor biosynthesis. This enzyme is responsible for transferring the first alpha-1,4-mannose to GlcN-acyl-PI during GPI precursor assembly, a key step in cell surface protein anchoring.
Therapeutic significance:
GPI mannosyltransferase 1 is implicated in Glycosylphosphatidylinositol biosynthesis defect 1, a disorder marked by portal vein thrombosis, portal hypertension, and early-onset cerebral infarctions among other symptoms. Understanding the role of GPI mannosyltransferase 1 could open doors to potential therapeutic strategies for this autosomal recessive disorder.